Skip to main content

Table 4 Cost-effectiveness results

From: The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation

Discounted results (Results per 2,000,000 people)

Current practice (CP)

Policy 1a

Policy 2b

Policy 3c

Policy 1 — CP

Policy 2 — CP

Policy 3 — CP

Life years (1,000)

19,515

19,580

19,564

19,601

65

49

86

QALYs (1,000)

12,006

12,103

12,082

12,188

97

76

182

Informal care (1,000)

4,975

4,947

4,953

4,898

−27

−22

−77

Days off sick (100)

1,733

1,705

1,711

1,673

−27

−21

−60

QALY loss due to depression (1,000)

1,746

1,695

1,702

1,631

−51

−44

−115

Costs (2013, £1,000,000)

29,626

30,676

34.475

36,431

1,050

4,849

6,805

Costs (2013 UK £1,000,000) Undiscounted

 Complications management

9,833

9,644

9,459

9,428

−190

−374

−405

 Annual review

9,134

9,222

9,200

9,294

88

66

161

 Primary care management

11,169

11,337

11,281

11,470

167

112

300

 Ongoing diabetes management (excluding above)

6,833

6,865

6,856

6,875

31

23

42

 Diagnostic interview

1,271

1,320

5,588

5,840

50

4,317

4,569

 Opportunistic screening

107

112

547

574

5

440

467

 Depression treatment

3,215

4,666

5,349

7,728

1,451

2,134

4,513

 Total cost

41,562

43,165

48,281

51,209

1,603

6,719

9,647

  1. CP Current practice, IHD Ischaemic heart disease, MI Myocardial infarction, CHF Congestive heart failure. aPolicy 1 = Collaborative care; bPolicy 2 = Opportunistic screening; cPolicy 3 = both collaborative care and opportunistic screening